diet physical*sustained weight loss*physical activity*medical monitoring*medical care setting*body weight*lifestyle intervention*weight maintenance*preference*choice*comprehensive*monthly contact*energy deficit*loss goal*least*behavioral therapy*obese*diet physical activity*intensive behavioral lifestyle*setting*such intervention*term weight*behavioral lifestyle*body weight weekly*necessary energy deficit*maintenance program*obese patient*loss maintenance*trained interventionists*individual*short*weight loss goal*short term weight*interventionist*effective*ongoing monitoring*comprehensive weight maintenance*focus*high intensity*weight maintenance counseling*meal replacement*medical*maintenance*lifestyle program*goal*program*loss sustained weight*health status*intensity*high*sustained weight*strategy*calorie diet*short term*deficit*woman*total*diet choice*group session*total meal replacement*baseline body weight*food*monitoring*maintenance counseling*loss such program*comprehensive weight loss*ongoing*loss*consumption*level*practitioner*high level*term weight loss*intensive*meal*nutrients*patient*baseline body*physical*calorie*term*trained interventionist*activity*therapy*trained practitioner*body*energy*diet*weight*weight weekly*weight maintenance program*medical care*counseling*comprehensive weight*intervention*behavioral*replacement*such program*type*month*weight loss maintenance*weight loss*lifestyle*necessary energy*optimal*benefit*participation*loss maintenance program*baseline*least monthly contact*total meal*care setting*close medical monitoring*behavioral lifestyle intervention*overweight*status*interventionists*diabetes*session*behavioral strategy
smoking behaviors*section*medical monitoring*assumption*retrospective analysis*death rate*smoking*banding*alcohol use*comprehensive*bariatric*study*obese*trial*effectiveness*obese patient*longer study*case fatality rate*individual*dependent*metabolic surgery*risk*stomach*cigarette smoking*feasible*effective*medical therapy*cohort*lifestyle support*medical*clinical*modeling*surgery*gastric banding*effective weight*program*optimal medical therapy*metabolic*alcohol*loss treatment*bariatric surgery*such study*gastric*modeling study*stomach stapling*pharmacological therapy*substance use*lifelong lifestyle*mortality determinants*lifelong lifestyle support*such patient*weight management program*treatment*severe obesity*comorbidities*small intestine*monitoring*cohort study*body mass index*surgical*loss*retrospective*obesity*control*adult*patient*substance*safety*mortality excess*decline mortality*analysis*pharmacological*therapy*weight loss treatment*weight*weight management*comprehensive weight*management program*mortality*type*recent study*profile*weight loss*lifestyle*optimal*bmi*procedure*benefit*comparator*effective weight loss*nonsurgical*cigarette*mortality differential*lifelong*smoking habit*drug*clinical trial*severe*comprehensive weight management*subject*relative risk*nonsurgical subject*intestine*metabolic profile*diabetes
diet physical*physical activity*lowering medication*weight loss medication*combination*behavioral counseling*choice*reproductive year*provider*potential benefit*least*inhibitor*obese*agonist*diet physical activity*knowledgeable*aglucosidase inhibitor*insufficient weight*approach*obese patient*successful weight loss*risk*effective*insufficient weight loss*adjunct*alternative*reproductive*treatment approach*neutral*glucose lowering*glucophage*successful weight*gain*weight gain*reliable*concomitant*woman*agent*metformin hydrochloride*treatment*diabetes provider*body mass index*efficacy*glucose lowering medication*loss*tolerability*medication*potential risk*glucose (beta-d)-isomer*loss medication*combination therapy*patient*product label*metformin*safety*female contraception*reliable method*physical*pharmacological*activity*glucose (alpha-d)-isomer*therapy*aglucosidase*diet*weight*pregnant*anhydrous dextrose*glucose (dl)-isomer*counseling*contraception*behavioral*type*month*label*glucose monohydrate*alternative medication*possible medication*weight loss*tolerability issue*concomitant medication*response*bmi*glucose*benefit*potential*male contraception*glucose (l)-isomer*insufficient*pharmacological treatment*alpha glucosidase*overweight*balance*relative risk*diabetes
metformin hydrochloride*activity goal*rate gfr*filtration rate*weight*physical activity*minimum*glycemic goal*glomerular filtration rate*monotherapy*counseling*water stress*glomerular filtration*ml*efficacy*relative risk*longstanding evidence base*min week*physical activity goal*goal metformin monotherapy*loss*filtration*glucophage*medication*goal*weight loss*ml min*lower gfr range*counseling setting*filtration rate gfr*week minimum*min*observational*lifestyle*lower*postmortem diagnosis*m2*most patient*goal metformin*lifestyle change*risk*setting*antemortem diagnosis*cardiovascular event*patient*body*evidence*intolerance*metformin monotherapy*nausea*glomerular*inexpensive*metformin*gfr*cardiovascular*safety*diagnosis*dose*effort*longstanding evidence*min week minimum*contraindication*lower gfr*physical*glycemic*lifestyle effort*observational data*evidence base*glycemic goal metformin*activity*dehydration*longstanding*gfr range
inhibitor glp1 analog*sulfonylurea dpp4*dpp4 inhibitor glp1*metabolic ketosis*postprandial hypoglycemia*study grade*combination*regimen*cost measures*dpp4 inhibitor*present*dpp iv*sulfonylurea*study*administration*basal*inhibitor*hyperglycemia*frequency*irregular meal*cost*effectiveness*glucagon like peptide*approach*irregular meal schedule*hypoglycemia*reduction*drug class sulfonylurea*major drug class*model*insulin*sulfonylurea dpp4 inhibitor*glycemic effect*effective*comparative effectiveness*medical*other drug*irregular*glp1 analog*secretagogues meglitinides*secretagogues*newer*late postprandial hypoglycemia*class sulfonylurea dpp4*effectiveness study grade*schedule*analog*toxicity*high*side effect*catabolic feature*medical psychosocial*insulin a chain*ketosis*glycemia reduction approach*situation*loss ketosis*high cost*agent*ongoing glycemia reduction*dpp4*grade*inhibitor glp1*economic outcome*specific situation*glucose toxicity*reduction approach*efficacy*ongoing*loss*cost-minimization analysis*feature weight loss*glucose (beta-d)-isomer*ketonuria*symptom*health economic outcome*basal insulin*iletin*weight loss ketosis*catabolic*meal*ongoing glycemia*control*moderate*patient*insulin b chain*meglitinides*meal schedule*drug class*acetonemia*glp1*comparative*class*combination regimen*glucose (alpha-d)-isomer*dpp 4*glycemic control*weight*anhydrous dextrose*glucose (dl)-isomer*economic*comparative effectiveness study*moderate glycemic effect*dipeptidyl peptidase*psychosocial*sodium insulin*cost analysis*catabolic feature weight*advantage*novolin*fasting hypoglycemia*postprandial*newer agent*glucose monohydrate*weight loss*cost comparison*glucose*class sulfonylurea*glp 1*major drug*feature weight*moderate glycemic*effectiveness study*glycemia reduction*glucose (l)-isomer*effect*drug*pricing*severe*glycemic*outcome*diabetes*glycemia
hba1c*glargine*sulfonylurea dpp4*adjunctive*insulin dosing*dpp4 inhibitor glp1*pioglitazone*social adjustment*complex*bolus*blood*postprandial hypoglycemia*combination*regimen*pharmacodynamic profile*cost measures*dpp4 inhibitor*glp1 receptor agonist*initiate*dpp iv*provider*sulfonylurea*progressive nature*administration*basal*inhibitor*serial lung function*complex insulin regimen*postprandial glucose excursion*receptor*agonist*suboptimal blood glucose*cost*postprandial glucose*suboptimal blood*accurate*remains*glucagon like peptide*nph*complex insulin*initiation*glucose excursion*hypoglycemia*testing*individual*basal insulin analog*bolus insulin dosing*insulin*lispro*risk*lung function testing*threat*pharmacodynamic*sulfonylurea dpp4 inhibitor*insulin analog*alternative*duration*dosing range*volume*initiate insulin therapy*glucose control*limited dosing range*potent*better absorption*injectable therapy*csii*initiate insulin*combination injectable therapy*noninsulin*insulin dos*goal*hemoglobin a1c*punishment*insulin regimen*newer*accurate dosing*lower*higher*comfortable*analog*blood glucose control*evidence*prandial*u300*thiazolidinediones*cover*dos adjunctive use*sodium glucose cotransporter*higher dos*insulin a chain*target*acceptable*blood sugar*failure*helpful*goal provider*smaller volume*insulin administration*longer duration*agent*dpp4*inhibitor glp1*preparation*glycemic goal*bolus insulin*glycemic goal provider*suboptimal*absorption*cost-minimization analysis*level*glucose (beta-d)-isomer*flexibility*insulin analog people*u300 glargine*basal insulin*iletin*sglt2*degludec*control*patient*insulin b chain*regimen flexibility*adjunctive use*mix*lung function*sglt2 inhibitor*limited dosing*prandial use*glp1*serial lung*u200 degludec*serial*expensive*glucose (alpha-d)-isomer*dos*therapy*dpp 4*a1c*function testing*noninsulin agent*concentrated preparation*smaller*anhydrous dextrose*glucose (dl)-isomer*dipeptidyl peptidase*glp1 receptor*sodium insulin*cost analysis*lung*novolin*fasting hypoglycemia*postprandial*sglt 2*type*u200*profile*progressive*glucose monohydrate*excursion*lower cost*injectable*part mix*cost comparison*blood glucose level*glucose*dosing*glp 1*acceptable fasting blood*adjustment*insulin therapy*receptor agonist*biphasic*glucose l-isomer*glucose level*analog people*critical*pricing*severe*glycemic*blood glucose*relative risk*diabetes*acceptable fasting
min week*metformin*agonist*weight loss*physical activity*m2*inhibitor*diabetes*glucose*medication*efficacy*min*lifestyle*counseling*weight*therapy*provider*loss*patient*effectiveness*profile*approach*ongoing*agent*severe*activity*risk*physical*type*meal*alternative*study*goal*medical*effective*safety*individual*combination*drug*setting*high*control*body*level
